MimiVax announces disappointing pivotal Phase IIb trial data for cancer vaccine

Even before this readout, KOLs were not excited about MimiVax's cancer vaccine in interviews with GlobalData. Even before this readout, KOLs were not excited about MimiVax's cancer vaccine in interviews with GlobalData. The treatment failed to show statistical OS benefit. Credit: RVillalon / Shutterstock.com Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth clinical trials industry analysis across drug development, clinical research, and trial innovation. With a free Clinical Trials Arena profile, you can: Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise. Hard data and deep insights on clinical…

Source: Clinical Trials Arena